Gefitinib or erlotinib combined with bevacizumab prolonged the PFS to 16.0 months in advanced‐stage NSCLC patients with EGFR‐activating mutations, but the OS was not significantly different.10, 13. Here, EGFR is linked to non-small cell lung carcinoma.